SCM
ACRS icon

Silverarc Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Silverarc Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,400
Closed -$16.4K – 69
2023
Q3 		$16.4K Buy
+2,400
New +$20.5K 0.01% 80

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Silverarc Capital Management's ACRS Position: Q3 2023 in Review

Silverarc Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 219,229 shares — an estimated $1.87M sold.

Silverarc Capital Management first reported a position in ACRS in Q1 2021 and held it in 10 quarters. The position peaked at $8.56M in Q3 2022. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • Silverarc Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 219,229 Aclaris Therapeutics shares in Q3 2023, an estimated $1.87M.
  • Silverarc Capital Management first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 10 quarters.
  • Silverarc Capital Management's Aclaris Therapeutics position peaked at $8.56M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.